About CLINUVEL

Dr Dennis Wright

BPharm MSc PhD

Acting Chief Scientific Officer

Dr Wright has a broad range of experience in the pharmaceutical industry spanning 25 years. He spent more than 17 years at CSL working predominantly in regulatory affairs with nearly a decade as Regulatory Affairs Manager.

During this time Dr Wright was responsible for the registration of a number of key products in Australia and the management of regulatory strategy for development projects.

Most recently he was Global Pharmacovigilance Manager and Regulatory Affairs Manager for the Australian and New Zealand operations of Mayne Pharma, a company recently acquired by Halcygen (ASX:HGN).

He has a Pharmacy degree and post-graduate qualifications from University of Sydney and Health Economics qualifications from Monash University, Melbourne. Dr Wright is responsible for leading the clinical and regulatory development team and progressing afamelanotide through to regulatory approval in global markets.

Latest Company Announcements

07 November 2017

Response to ASX Price Query

Response to ASX Price Query

Read More
30 October 2017

Appendix 4C

Appendix 4C

Read More
26 October 2017

Appendix 4G

Appendix 4G

Read More
16 October 2017

CLINUVEL Newsletter - October 2017

I am addressing you during quite a turbulent period, when our teams are preparing various dossiers to meet regulatory obligations in Europe and the US

Read More
10 October 2017

CLINUVEL CONFIRMS AGM DATE

CLINUVEL PHARMACEUTICALS LTD today announced it will hold its 2017 Annual General Meeting of shareholders on Tuesday 28 November 2017

Read More

Quick Links